Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

265.85
-2.1900-0.82%
Post-market: 266.400.5500+0.21%19:25 EDT
Volume:7.90M
Turnover:2.10B
Market Cap:640.51B
PE:30.79
High:267.77
Open:267.13
Low:265.17
Close:268.04
52wk High:276.47
52wk Low:173.33
Shares:2.41B
Float Shares:2.40B
Volume Ratio:1.30
T/O Rate:0.33%
Dividend:5.24
Dividend Rate:1.97%
EPS(TTM):8.64
EPS(LYR):11.03
ROE:25.74%
ROA:8.59%
PB:7.54
PE(LYR):24.10

Loading ...

Johnson & Johnson’s Rybrevant Faspro™ (Amivantamab and Hyaluronidase-Lpuj) Receives U.S. FDA Priority Review as Potential First-in-Class Egfr- and Met-Targeted Subcutaneous Treatment for Advanced Head and Neck Cancer

THOMSON REUTERS
·
Jul 30

PRESS Digest -Wall Street Journal - July 30

Reuters
·
Jul 30

Dow Jones Top Company Headlines at 9 PM ET: Samsung's Chip Earnings Push Net Profit to Record | Microsoft ...

Dow Jones
·
Jul 30

Johnson & Johnson Updates Guidance After Firefly, Sail Deals

TIPRANKS
·
Jul 30

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

THOMSON REUTERS
·
Jul 30

Johnson & Johnson sees Firefly, Sail Biomedicines dilute FY27 EPS by $1.36

TIPRANKS
·
Jul 30

Johnson & Johnson Partners with Sail Biomedicines on in Vivo CAR-T Programs, Takes Option to Buy Sail for $2.58 Billion

Reuters
·
Jul 30

Johnson & Johnson Makes $465 Million Equity Investment in Sail Biomedicines

Reuters
·
Jul 30

Johnson & Johnson Lowers 2026 Profit Forecast

Reuters
·
Jul 30

Johnson & Johnson Completes USD 1 Billion Acquisition of Firefly Bio

Reuters
·
Jul 30

JNJ enters strategic agreement to acquire Sail Biomedicines for $2.58B

TIPRANKS
·
Jul 30

Johnson & Johnson cuts FY26 EPS view to $10.86-$11.01, consensus $11.68

TIPRANKS
·
Jul 30

Johnson & Johnson affirms FY26 revenue view of $100.8B-$101.4B

TIPRANKS
·
Jul 30

Perrigo Co. PLC Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 30

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in Vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

THOMSON REUTERS
·
Jul 30

J&J: Granted Exclusive Option to Acquire Sail Biomedicines for $2.58Bln

THOMSON REUTERS
·
Jul 30

J&J: Johnson & Johnson Will Also Make an Equity Investment in Sail

THOMSON REUTERS
·
Jul 30

Johnson & Johnson Fy2026 Shr View $11.69

THOMSON REUTERS
·
Jul 30

J&J Outlook FY Adj EPS $10.96 - $11.11

THOMSON REUTERS
·
Jul 30

J&J - Enters Strategic Agreements with Sail Biomedicines - SEC Filing

THOMSON REUTERS
·
Jul 30